Adtralza 150 mg

ADTRALZA 150 MG is a subcutaneous solution containing tralokinumab, used for managing moderate to severe atopic dermatitis. This biologic therapy targets specific immune pathways to help reduce inflammation and improve skin condition.

ADTRALZA 150 MG is primarily used for the treatment of moderate to severe atopic dermatitis in adults. This condition, also known as eczema, causes red, itchy, and inflamed skin. Tralokinumab works by targeting interleukin-13, a protein involved in the inflammatory process. Patients often seek this medication to alleviate symptoms and improve their quality of life.

Common effects of ADTRALZA 150 MG may include injection site reactions, such as redness, itching, or swelling. Some users might experience eye and eyelid inflammation, conjunctivitis, or cold symptoms. These effects vary among individuals and are not experienced by everyone.

ADTRALZA 150 MG should be used with caution in patients with a history of eye problems or parasitic infections. It is important to follow the advice of a healthcare provider regarding the administration and monitoring of this medication. Always store the solution properly to maintain its effectiveness.

ADTRALZA 150 MG may interact with other medications, including those that affect the immune system. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of tralokinumab.